AWMSG MEETING TO BE HELD
WEDNESDAY, 12th JUNE 2013
COMMENCING 10.30 AM (UNTIL 4.00 PM APPROX)
AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN

AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Chairman’s report (verbal update)
5. Minutes of previous meeting
   1/AWMSG/0613
6. Appraisal 1 – Full submission
   Ceftaroline fosamil (Zinforo®) for the treatment of the following
   infections: complicated skin and soft-tissue infections (cSSTI)
   and community-acquired pneumonia (CAP)
   2/AWMSG/0613 Appendices
7. Appraisal 2 – Full submission
   Adalimumab (Humira®) for the treatment of adults with severe
   axial spondyloarthritis without radiographic evidence of
   ankylosing spondylitis but with objective signs of
   inflammation by elevated CRP and/or MRI, who have had an
   inadequate response to, or are intolerant to nonsteroidal anti-
   inflammatory drugs
   3/AWMSG/0613 Appendices
8. Appraisal 3 – Full submission
   C1-esterase inhibitor (Berinert®) for the treatment of acute
   episodes of hereditary angioedema type I and II (HAE)
   4/AWMSG/0613 Appendices
9. Date of next meeting:
   Wednesday 17th July in Cardiff

Proceedings held in public will close and, to protect commercial confidentiality,
Appraisal 3 will be conducted in private.
The final appraisal recommendation will be announced in public.

Enclosure